Spirometric tests and CO transfer tests were systematically employed before, during, after the therapy and in the follow-up of 33 patients affected by non seminomatous testicular tumors treated with 4-5 Einhorn courses (PVB). The aim was to demonstrate possible bleomycin-induced pulmonary toxicity and its relationship with the cumulative dose of the drug. Our patients, who never had clinical or radiological signs of pulmonary toxicity, did not show significant change in the functional respiratory tests throughout therapy, except for 6 patients who had a reduction in CO transfer of about 30 % after the 2nd or 3rd course which persisted up to the end and during the follow-up. We did not find any correlation of such a reduction with predisposing factors.
Get full access to this article
View all access options for this article.
References
1.
BlumR.H., CarterS.K., AgreK.: A clinical review of bleomycin, a new antineoplastic agent. Cancer, 31: 903–914, 1973.
2.
ComisR.L., KuppingerM.S., GinsbergS.J., CrookeS.T., GilbertR., AuchinlossJ.H., PrestaykoA.W.: Role of single-breath carbon monoxide-diffusing capacity in monitoring the pulmonary effects of bleomycin in germ cell tumor patients. Cancer Res., 39: 5076–5080, 1979.
3.
CrookeS.T., EinhornL.H., ComisR.L., D'AoustJ.C., PrestaykoA.W.: The effect of prior exposure to bleomycin on the incidence of pulmonary toxicities in a group of patients with disseminated testicular carcinoma. Med. Pediatr. Oncol., 5: 93–98, 1978.
4.
DinakaraP., BlumenthalW.S., JohnstonR.F., KaufmannL.A., SolnickP.B.: The effect of anemia on pulmonary diffusing capacity with derivation of a correct equation. Am. Rev. Respir. Dis., 102: 965–969, 1970.
5.
EinhornL.H., DonohueJ.: Cisdiamminedichlorplatinum, vinblastine and bleomycin combination chemotherapy in disseminated testicular cancer. Ann. Intern. Med., 87: 293–298, 1977.
6.
FornasieroA., DanieleO., PaccagnellaA., FosserV., CarteiG., FerrazziE., FiorentinoM.: Tossicità della bleomicina somministrata in infusione continua ad alte dosi. Tumori, 66: 607–613, 1980.
7.
GoldinerP.L., SchweizerO.: The hazards of anesthesia and surgery in bleomycin-treated patients. Semin. Oncol., 6: 121–124, 1979.
8.
HaasCh., HaguetJ.F., BassetJ.M., LebasF.X., ChoubracF.: Les fibroses pulmonaires de la bléomycine. Therapie, 31: 723–731, 1976.
9.
HomassonJ.P., RoullierA., BoissonotE., GarandG., LavandierM.: Altérations de la diffusion alvéolo-capillaire au cours des traitements par la bléomycine. Ann. Otolaryngol. Chir. Cervicofac, 91: 383–402, 1974.
10.
HomassonJ.P., BoissinotE., RoullierA., MolineJ.: Constance de l'altération du transfert alvéolo capillaire chez l'homme par un agent anti-tumoral (bléomycine). Nouv. Presse Méd., 17: 1103, Avril, 1974.
11.
HorowitzA.L., FriedmannM., SmithG., YagodaA., La MonteC., LairdW.R.: The pulmonary changes of bleomycin toxicity. Radiology, 106: 65–68, 1973.
12.
IzbickiR.M., BakerL.H.: Prediction of early pulmonary toxicity due to bleomycin in cancer patients treated with combination therapy. Proc. Am. Soc. Clin. Oncol., 18: 345, 1977.
13.
KrakoffJ.H., CvitkovicE., CurrieV., YenS., La MonteC.: Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer, 40: 2027–2037, 1977.
14.
LaccourreyeH., HaasC., BassetJ.M., HaguetJ.F.: Toxicité pulmonaire de la Bléomycine. Ann. Otolaryngol. Chir. Cervicofac, 94: 571–582, 1977.
15.
La MonteC.S., YagodaA., KrakoffI.H.: Pulmonary function changes in patients treated with bleomycin. Clin. Res., 19: 494, 1971.
16.
MolineJ., HomassonJ.P., GarandG., GasseJ., BoissinotE., RoullierE.: Devenir des malades traités par la bléomycine et évolution à distance du transfert de l'oxyde de carbone. Thérapie, 31: 241–246, 1976.
17.
MonfardiniS., FossatiV., PizzocaroG., VillaE.: Vinblastine plus bleomycin continuous infusion chemotherapy of stage III testicular carcinomas. Tumori, 67: 117–123, 1981.
18.
PascualR.S., MosherM.B., SikandR.S., De ContiR.C., BouhuysA.: Effects of bleomycin on pulmonary function in man. Am. Rev. Resp. Dis., 108: 211–217, 1973.
19.
RanfaingJ., GuillierM.L., Simon-RigaudM.L., BanzetM.L., LedouxA.: Les fibroses pulmonaires à la bléomycine. Poumon. Coeur, 33: 117–122, 1977.
20.
RoujeauJ., NarcyPh., MarsanC., TrotouxJ.: Fibrose pulmonaire et Bléomycine. Sem. Hôp. Paris, 49: 1969–1994, 1973.
21.
SamuelsM.L., JohnsonD.E., HoloyeP.Y., LanzottiV.J.: Large dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy. JAMA, 235: 1117–1120, 1976.
22.
SteelR.G.D., TorrieJ.H.: Analysis of variance of groups with unequal replication and Dupnett's procedure for comparing all means with a control. In: Principles and Procedures of Statistics.StellR.G.D., and TorrieJ.H. (eds.), pp. 111–115, McGraw Hill, New York, 1968.
23.
ValicentiJ.F., ReddingR.A., SteinM.: Bleomycin effect on pulmonary function in beagles. Physiologist, 15: 292, 1972.
24.
VicenteJ., Cortes-FunesH., San RomanC., MartinezJ., Perez-GuerreroJ., NavarroV.: Bleomycin: Pulmonary function alterations. XI Int. Cancer Congress-Workshop12(abstracts) Florence, 1974.
25.
YagodaA., MukerjiB., YoungC., EctubanasE., La MonteC., SmithJ.R., TanC.T.C., KrakoffJ.H.: Bleomycin, an antitumor antibiotic-clinical experience in 274 patients. Ann. Intern. Med., 77: 861–870, 1972.
